Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Eye Drops & Ophthalmic Recalls

Recalls of ophthalmic solutions and eye drops - a category hit by widely reported contamination recalls.

673 recalls in this category, newest first.

Class I · High risk

Carboxymethylcellulose Sodium 0.5% Ophthalmic Solution

Non-Sterility: Customer complaints of mold in the product after use and handling due to the fact that the preservative used in the lots of Carboxymethylcellulose Sodium 0.5% Ophthalmic Solution may not be effective through expiry.

Terminated Sterility / contamination Altaire Pharmaceuticals, Inc. D-375-2014
Class II · Moderate risk

Latanoprost Ophthalmic Solution

Lack of Assurance of Sterility: Failed at expiry for Preservative Effectiveness Test (PET), therefore the product may be susceptible to microbial growth before the expiry date.

Terminated Sterility / contamination Apotex Inc NDC 60505-0565-1 D-852-2013
Class II · Moderate risk

BNP/Dexamethasone Eye Ointment

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Ongoing Sterility / contamination Lowlite Investments, Inc. D/B/A Olympia Pharmacy D-707-2013
Class II · Moderate risk

Cyclosporin

Lack of Assurance of Sterility:All sterile products compounded, repackaged, and distributed by this compounding pharmacy due to lack of sterility assurance and concerns associated with the quality control processes.

Terminated Sterility / contamination Axium Healthcare Pharmacy dba Balanced Solutions Compounding D-278-2013
Class II · Moderate risk

Vancomycin Ophthalmic PF

Lack of Assurance of Sterility; FDA inspectional findings resulted in concerns associated with quality control procedures that impacted sterility assurance

Terminated Sterility / contamination Pallimed Solutions D-880-2013
Class II · Moderate risk

Tacrolimus Ophthalmic

Lack of Assurance of Sterility; FDA inspectional findings resulted in concerns associated with quality control procedures that impacted sterility assurance

Terminated Sterility / contamination Pallimed Solutions D-875-2013
Class II · Moderate risk

Cyclosporine Ophthalmic

Lack of Assurance of Sterility; FDA inspectional findings resulted in concerns associated with quality control procedures that impacted sterility assurance

Terminated Sterility / contamination Pallimed Solutions D-864-2013
Class II · Moderate risk

Acetylcysteine Ophthalmic Solution

Lack of Assurance of Sterility; FDA inspectional findings resulted in concerns associated with quality control procedures that impacted sterility assurance

Terminated Sterility / contamination Pallimed Solutions D-857-2013
Class II · Moderate risk

Ophthalmic dilation gel

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-659-2013
Class II · Moderate risk

Ophthalmic dilation gel

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-658-2013
Class II · Moderate risk

Latanoprost 0.025% eye drop

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-650-2013
Class II · Moderate risk

Laser ophthalmic drops

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-649-2013
Class II · Moderate risk

Itraconazole 1% eye ointment

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-648-2013
Class II · Moderate risk

Cyclosporine 2% ophthalmic

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-637-2013
Class III · Low risk

Tobramycin Ophthalmic Oint.

Labeling: Label Mix-up: The affected units were labeled incorrectly describing the product as "ointment" instead of "solution."

Terminated Labeling / mix-up Stat Rx USA NDC 16590-224-05 D-050-2013
Class II · Moderate risk

Glycerin 99.5% Ophthalmic 10 Ml

Lack of Assurance of Sterility: Franck's Lab Inc. initiated a recall of all Sterile Human Drugs distributed between 11/21/2011 and 05/21/2012 because FDA environmental sampling revealed the presence of microorganisms and fungal growth in the clean room where sterile products were prepared.

Terminated Sterility / contamination Franck's Lab Inc., d.b.a. Franck's Compounding Lab D-1530-2012
Class II · Moderate risk

Gentamicin 40mg/Ml

Lack of Assurance of Sterility: Franck's Lab Inc. initiated a recall of all Sterile Human Drugs distributed between 11/21/2011 and 05/21/2012 because FDA environmental sampling revealed the presence of microorganisms and fungal growth in the clean room where sterile products were prepared.

Terminated Sterility / contamination Franck's Lab Inc., d.b.a. Franck's Compounding Lab D-1528-2012
Class II · Moderate risk

Fluorouracil

Lack of Assurance of Sterility: Franck's Lab Inc. initiated a recall of all Sterile Human Drugs distributed between 11/21/2011 and 05/21/2012 because FDA environmental sampling revealed the presence of microorganisms and fungal growth in the clean room where sterile products were prepared.

Terminated Sterility / contamination Franck's Lab Inc., d.b.a. Franck's Compounding Lab D-1520-2012
Class II · Moderate risk

Ethyl Alcohol 10% Injectable 30 Ml

Lack of Assurance of Sterility: Franck's Lab Inc. initiated a recall of all Sterile Human Drugs distributed between 11/21/2011 and 05/21/2012 because FDA environmental sampling revealed the presence of microorganisms and fungal growth in the clean room where sterile products were prepared.

Terminated Sterility / contamination Franck's Lab Inc., d.b.a. Franck's Compounding Lab D-1516-2012
Class II · Moderate risk

Epinephrine **

Lack of Assurance of Sterility: Franck's Lab Inc. initiated a recall of all Sterile Human Drugs distributed between 11/21/2011 and 05/21/2012 because FDA environmental sampling revealed the presence of microorganisms and fungal growth in the clean room where sterile products were prepared.

Terminated Sterility / contamination Franck's Lab Inc., d.b.a. Franck's Compounding Lab D-1514-2012